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Objectives  To evaluate dermoscopic features in a group of 127 patients with mastocytosis in the 
skin and to investigate the relationship between different dermoscopic patterns and other clinical 
and biological characteristics of the disease. 
Design  Clinical and laboratory data were compared among patients with mastocytosis grouped 
according to the different dermoscopic patterns. 
Setting  Patients were selected from the Instituto de Estudios de Mastocitosis de Castilla La 
Mancha and the Department of Dermatology of Hospital Universitario Ram ón y Cajal from April 1 
through September 30, 2009. 
Patients  Overall, 127 consecutive patients (70 females [55.1%] and 57 males [44.9%]; median age, 
17 years; range, 0-81 years) with mastocytosis in the skin were included in the study. 
Main Outcome Measures  Evaluation of dermoscopic patterns and investigation of potential 
predictive factors for more symptomatic forms of the disease according to the need for daily 
antimediator therapy. 
Results  Four distinct dermoscopic patterns were observed: yellow-orange blot, pigment network, 
reticular vascular pattern, and (most frequently) light-brown blot. A reticular vascular pattern was 
identified in all telangiectasia macular eruptiva and some maculopapular mastocytosis. In turn, all 
patients with mastocytoma displayed the yellow-orange blot pattern. The reticular vascular 
dermoscopic pattern was associated with the need for daily antimediator therapy; this pattern, 
together with serum tryptase levels and plaque-type mastocytosis, represented the best combination 
of independent factors to predict the need for maintained antimediator therapy. 
Conclusions  Dermoscopy is a feasible method for the subclassification of mastocytosis. Of note, a 
reticular vascular pattern is more frequently associated with the need for antimediator therapy. 
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Figures in this Article 
Skin is the most commonly involved tissue in mastocytosis, being affected in virtually all pediatric 
and most adult cases.1 - 6 Because a complete bone marrow study is required to establish the systemic 
nature of the disease, the term mastocytosis in the skin (MIS) recently has been proposed to define 
those patients (eg, children with proven cutaneous mastocytosis) in whom screening for systemic 
involvement has not been performed. 
According to the World Health Organization, MIS may be subclassified into 3 variants: 
maculopapular cutaneous mastocytosis (MPCM) (also known as urticaria pigmentosa [UP]), diffuse 
cutaneous mastocytosis, and solitary mastocytoma of the skin.7 The most common variant is MPCM, 
which is found in children and adults with mastocytosis; diffuse cutaneous mastocytosis and solitary 
mastocytoma of the skin are less frequently observed and typically are restricted to pediatric 
patients. In addition, telangiectasia macularis eruptiva perstans (TMEP) also has been reported as a 
rare subvariant of MIS characterized by reddish macules that occur due to underlying, dilated, 
dermal, thin-walled blood vessels; it is typically seen in adults.8 - 10 More recently, (multiple) nodular 
and plaque-type skin lesions also have been described.11 They have been proposed as new variants of 
MIS on the basis of the underlying clinical and pathogenic mechanisms. 
Although careful inspection of skin lesions frequently suffices to identify MIS, a skin biopsy followed 
by histologic evaluation plus immunohistochemistry for tryptase and c-kit are required to reach a 
final diagnosis.12 Histologic criteria for the diagnosis of MIS include the presence of large aggregates 
(>15 cells per cluster) of tryptase-positive mast cells (MCs) or scattered MCs exceeding 20 cells per 
microscopic high-power ( ×40) field.13 - 14 In a variable percentage of cases, c-kit mutation at codon 
816 also is detected in lesional skin.15 - 16  
Dermoscopy is a noninvasive technique based on in vivo epiluminescence microscopy, which 
provides rapid and easy evaluation of the colors and microstructure of the epidermis, the 
dermoepidermal junction, and the papillary dermis, none of which are visible to the naked eye. In 
recent years, dermoscopy has emerged as a simple and useful tool for the diagnosis of melanocytic 
and nonmelanocytic skin lesions, and it has proven to be especially useful for early recognition of 
malignant melanoma.17 Several diagnostic algorithms based on the use of dermoscopy have been 
developed for melanocytic and nonmelanocytic skin lesions. However, currently, information 
regarding the dermoscopic patterns of skin lesions in mastocytosis is scanty and restricted to 
individual case reports or very small patient series.18 - 19 In this study, we report on the dermoscopic 
patterns of a large series (n  =  127) of patients with mastocytosis and the relationship between those 
patterns and the clinical and biological characteristics of the disease. 
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PATIENTS AND CLINICAL AND LABORATORY EXAMINATIONS 
Overall, 127 consecutive patients (70 females [55.1%] and 57 males [44.9%]; median age, 17 years; 
range, 0-81 years) with MIS who were referred to the Instituto de Estudios de Mastocitosis de 
Castilla La Mancha or the Department of Dermatology of Hospital Ram ón y Cajal from April 1 
through September 30, 2009, were included in the study. Among the 127 patients, 61 (48.0%) were 
younger than 14 years and 66 (52.0%) were adults (median [range] age at the time of dermoscopy, 3 
years [0-11 years] and 38 years [15-81 years], respectively). In all patients except those with 
mastocytoma who had typical clinical features at arrival, the diagnosis of MIS was established on 
the basis of a skin biopsy specimen. Median (range) time from disease onset to inclusion in the 
study was 11 years (3-60 years) in adults and 1 year (0-8 years) in children (P   <  .001).  
The study was approved by the local ethics committees, and each participant gave informed consent 
before entering the study, according to the tenets of the Declaration of Helsinki. 
Classification of MIS was performed in all patients after careful examination of the skin following 
the criteria proposed by Hartmann and Henz (Table 1).11 Serum baseline tryptase (sBt) 
measurement was performed using a commercially available technique (CAP; Phadia AB, Uppsala, 
Sweden); clinical symptoms suggesting the release of MC mediators (eg, pruritus, flushing, 
abdominal cramping, diarrhea, nausea or vomiting, and anaphylaxis) also were recorded. The 
severity of mastocytosis-related symptoms was subsequently graded in 2 different subgroups 
according to the need for antimediator therapy (AMT) on a daily basis. 
Table 1. Classification of Cutaneous Mastocytosis by Hartmann and Henz11  
  
DERMOSCOPY 
Mastocytosis skin lesions were examined by 2 independent dermatologists trained in dermoscopy 
(S.V.-G. and E.D.L.H.) using a DermLite instrument (3Gen LLC, Dana Point, California) at 10-fold 
magnification. No pressure was applied to avoid collapse of the capillaries. In those patients who 
displayed multiple skin lesions, 2 or more lesions were evaluated. According to the dermoscopic 
findings (eg, background color and the presence or absence of reticular lines or vessels), as many as 
4 different dermoscopic patterns were identified, and each patient's lesions were classified into 1 of 
these 4 subgroups. Subsequently, the potential relationship between the dermoscopic patterns 
identified and specific clinical variants of the disease, sBt levels, and the severity of MC mediator 
symptoms was investigated. 
The interobserver and intraobserver reproducibility was assessed for each dermoscopic pattern 
evaluated for a lesion in all 127 patients. The evaluation of dermoscopic patterns was masked from 
clinical data. Digital dermoscopic images were obtained from all patients by 4 investigators (S.V.-G., 
I. Á.-T., A.M., and L.E.), and the dermoscopic images were evaluated by 3 dermatologists (S.V.-G., 
E.D.L.H, and P.J.) who established the predominant dermoscopic pattern in each case. Regarding 
intraobserver reproducibility, 1 of the dermatologists (S.V.-G.) evaluated each lesion and 
reevaluated all of them 3 months later. Regarding interobserver reproducibility, 2 dermatologists 
(E.D.L.H. and S.V.-G.) independently evaluated the same lesions, and the results were compared. 
STATISTICAL ANALYSES 
For all continuous variables, median and range were calculated but for categorical variables, 
frequencies were reported. The Mann-Whitney and χ2 tests were used to assess the statistical 
significance of differences observed between groups for continuous and categorical variables, 
respectively. The κ statistics were calculated to assess interobserver and intraobserver agreement. 
With regard to the interpretation of κ statistics, a value of 1.00 indicates perfect agreement, values 
greater than 0.80 are considered excellent, values between 0.61 and 0.80 are good, values between 
0.40 and 0.60 are fair, and values less than 0.40 are poor. To identify the best combination of 
independent factors associated with each subgroup of patients, multivariate (ie, logistic regression) 
analysis was performed. For multivariate analyses, only those variables that showed statistically 
significant differences in the univariate study were included in the model. P   ≤  .05 was considered 
statistically significant. For all statistical analyses, the SPSS 15.0 statistical software package (SPSS 
Inc, Chicago, Illinois) was used. 
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CLINICAL VARIANTS OF MIS 
Overall, the different subtypes of MIS observed in the 127 patients studied were MPCM in 90 
patients (70.9%), nodular mastocytosis (NM) in 11 patients (8.7%), solitary mastocytoma in 11 
patients (8.7%), plaque-type mastocytosis (PM) in 8 patients (6.3%), and TMEP in 7 patients 
(5.5%). All patients except those with solitary mastocytoma displayed multiple skin lesions. Table 2 
gives the distribution of the different clinical variants according to patient sex and age. 
Table 2. Number (Percentage) of Different Variants of Lesions in Patients With Mastocytosis in the 
Skin Grouped According to Age and Sex  
  
DERMOSCOPIC FEATURES 
After careful examination of skin lesions, 4 dermoscopic patterns were identified (Figure 1) and 
named as follows: light-brown blot (51 patients [40.2%]), pigment network (41 patients [32.3%]), 
reticular vascular (18 patients [14.2%]), and yellow-orange blot (17 patients [13.4%]). In our study, 
the intraobserver and the interobserver agreement for the assignment of a dermoscopic pattern for 
each lesion were excellent ( κ  =  0.87, P   <  .001, and κ  =  0.80, P   <  .001, respectively). Of note, in 
all patients who displayed multiple skin lesions, a predominant dermoscopic pattern was identified. 
The light-brown blot pattern was characterized by a light-brownish diffuse blot without any other 
identifiable features; pigment network lesions showed fine brown reticular lines, similar to those 
observed in some melanocytic lesions. In turn, lesions with a reticular vascular pattern consisted of 
thin reticular telangiectasias on a mild erythematous base with sparse vessels dotted throughout. 
Finally, yellow-orange blot lesions were characterized by a yellowish to orange faded color with an 
ill-defined margin. Of interest, the dermoscopic patterns observed for different skin lesions of the 
same patient were similar. The histologic correlation of each dermoscopic pattern is illustrated in 
Figure 2. 
Figure 1. Examples of the 4 different dermoscopic patterns identified in patients with mastocytosis 
in the skin. A, In a 9-year-old boy, maculopapular cutaneous mastocytosis with a light-brownish 
blot were observed on dermoscopy without any identifiable dermoscopic structure (ie, the 
characteristic light-brown blot pattern). B, In a 7-year-old boy, maculopapular cutaneous 
mastocytosis and a light-brown blot were observed on dermoscopy. C, In a 25-year-old woman, 
maculopapular cutaneous mastocytosis and fine brown reticular lines were observed on 
dermoscopy, typical of the pigment network pattern. D, In a 57-year-old man, maculopapular 
cutaneous mastocytosis and a pigment network pattern were observed on dermoscopy. E, In a 59-
year-old woman, maculopapular cutaneous mastocytosis and thin reticular telangiectasias on a mild 
erythematous base with sparse vessels dotted throughout were observed on dermoscopy (ie, the 
reticular vascular dermoscopic pattern). F, In a 46-year-old woman, telangiectatic mastocytosis and 
a reticular vascular dermoscopic pattern were observed on dermoscopy. G, In a 9-month-old boy, 
solitary mastocytoma manifesting as a yellowish to orange discoloration with an ill-defined margin 
was observed on dermoscopy (ie, the yellow-orange blot dermoscopic pattern). H, In a 4-month-old 
girl, solitary mastocytoma and a yellow-orange blot were observed on dermoscopy. 
  
 
Figure 2. Histologic correlation with the 4 dermoscopic patterns (hematoxylin-eosin, original 
magnification ×40). A, The light-brown pattern showed mild and homogeneous hyperpigmentation 
of the basal layer associated with a dense dermal infiltrate of mast cells with scattered eosinophils. 
B, The pigmented network pattern correlated with a marked hyperpigmentation of the basal layer, 
more marked on the rete ridges, associated with a slight dermal infiltrate of mast cells. C, The main 
histopathologic feature of lesions with reticular vascular pattern was the dilation of the blood 
vessels. D, The yellow-orange blot pattern showed a dense infiltration of mast cells along the 
papillary and reticular dermis. 
  
 
 
Table 3 gives the distribution of the 4 dermoscopic patterns among adult and pediatric patients. The 
reticular vascular pattern was observed in 14 of the 66 adults (21.2%) and 4 of the 61 children 
(6.6%) (P  =  .02), but the yellow-orange blot pattern was more frequently found in children than 
adults (26.2% vs 1.5%; P   <  .001). By contrast, no significant differences in the frequency of the 
light-brown blot or the pigment network patterns were observed in adults compared with children 
(37.9% vs 42.6% and 39.4% vs 24.6%, respectively; P  =  .61 and P  =  .08, respectively). Figure 3 
shows the frequency of each dermoscopic pattern observed among the distinct MIS variants. A light-
brown blot pattern was observed in approximately half of all patients with MPCM lesions (43 of 90; 
[47.8%]), 3 of 11 patients with NM (27.3%), and 5 of 8 patients with PM (62.5%). In turn, a pigment 
network pattern was identified in 36 patients with MPCM (40.0%), 5 with NM (45.5%), and 3 with 
PM (37.5%). A reticular vascular pattern was seen in all adult patients with TMEP and in 11 (7 adults 
and 4 children); of 90 patients with MPCM (12.2%) finally, a yellow-orange blot was observed in all 
patients with mastocytoma and in 6 of 11 with NM (54.6%). 
 
 
 
 
Figure 3. Relative distribution of the different dermoscopic patterns observed among the patients 
with mastocytosis in the skin (MIS) (n  =  127), grouped according to the distinct forms of the 
disease. MPCM indicates maculopapular cutaneous mastocytosis; NM, nodular mastocytosis; PM, 
plaque-type mastocytosis, and TMEP, telangiectasia macularis eruptiva perstans. 
  
 
 
Table 3. Number (Percentage) of Dermoscopic Patterns According to Patient Age and Sex  
  
 
SERUM TRYPTASE 
The median (range) sBt level was 9 ng/mL (1-508 ng/mL) with significantly (P   <  .001) higher 
values in adults compared with children (median, 24.5 vs 6 ng/mL, respectively). Of interest, sBt 
levels were significantly higher in patients with a reticular vascular pattern vs those with the light-
brown blot (P  =  .02), pigment network (P  =  .02), or yellow-orange blot profile (P   <  .001) 
(median, 24.5 vs 10 ng/mL, 9 ng/mL, and 5.4 ng/mL, respectively) (Figure 4A), with the level in 
those with the yellow-orange blot profile being significantly lower than in those with the light-brown 
blot (P  =  .02) and pigment network patterns (P  =  .04). Of note, all these differences lost their 
statistical significance when adult and pediatric patients were separately considered except for the 
higher sBt levels found among children with reticular vascular vs yellow-orange blot patterns (10.5 
vs 5.2 ng/mL; P  =  .03). 
Figure 4. Median serum baseline tryptase levels in patients with mastocytosis in the skin (MIS) (n 
 =  127). Patients are grouped according to the different dermoscopic patterns identified (A) and the 
distinct skin variants of the disease (B). MPCM indicates maculopapular cutaneous mastocytosis; 
NM, nodular mastocytosis; PM, plaque-type mastocytosis; and TMEP, telangiectasia macularis 
eruptiva perstans. Error bars indicate SD. 
  
 
 
 
Figure 4B shows differences in sBt levels between the distinct clinical forms of MIS. Of interest, sBt 
levels were significantly higher in the TMEP group (median, 84.9 ng/mL) vs all other groups except 
for the patients with PM (MPCM, 21.7 ng/mL [P  =  .001]; NM, 9.8 ng/mL [P  =  .003]; and solitary 
mastocytoma, 4.2 ng/mL [P   <  .001]). Conversely, sBt levels in patients with mastocytoma were 
significantly lower than those of the remaining disease groups (P  =  .001). When dividing all 
patients into adult or pediatric groups, differences in sBt levels were restricted to TMEP vs MPCM 
(84.9 vs 21.7 ng/mL; P  =  .009) and PM vs MPCM (288 vs 21.7 ng/mL; P  =  .005) in adults; 
however, in children, only patients with mastocytoma showed significantly lower sBt levels 
compared with all other groups except patients with PM. 
NEED FOR ANTIMEDIATOR THERAPY 
In 75 patients (59.1%), mastocytosis-related symptoms were mild or absent, and patients did not 
need AMT or only needed it on demand; conversely, in the remaining 52 patients (40.9%), daily 
need for AMT was observed due to maintained symptoms. The percentage of patients who needed 
daily AMT was significantly higher among adults compared with children (51.5% vs 29.5%; P  =  .01) 
and in those patients with increased sBt levels of 10 ng/mL or greater compared with patients with 
sBt levels less than 10 ng/mL (66.7% vs 15.6%; P   <  .001) independent of the age group (65.3% vs 
11.8% [P   <  .001] in adults and 71.4% vs 17.0% [P   <  .001] in children). Regarding the association 
between AMT and the clinical forms of the disease, patients with PM needed continuous AMT more 
frequently than all other groups (87.5% vs 37.8%; P  =  .008), but none of the patients with solitary 
mastocytoma (compared with 44.8% of all other clinical forms of MIS; P  =  .003) required AMT on 
a daily basis. 
Regarding dermoscopic patterns (Table 4), the need for daily AMT was higher among patients with 
a reticular vascular pattern vs all other dermoscopic patterns (77.8% vs 34.9%; P  =  .001); in 
contrast, only 17.6% of patients with a yellow-orange blot pattern needed daily AMT (compared with 
44.5% of patients with other dermoscopic patterns). Of note, of those 17 patients (11 with 
mastocytoma and 6 with NM) with a yellow-orange blot pattern, the patients with NM needed 
continuous AMT more frequently than patients with mastocytoma (50.0% vs 0%; P  =  .03). In 
contrast, no significant differences were observed in the daily need for AMT among the 18 patients 
with a reticular vascular pattern (81.8% of patients with MPCM compared with 71.4% of patients 
with TMEP; P   >  .99). However, when patients with MPCM were separately considered, a higher 
frequency of need for daily AMT was observed among those with a reticular vascular pattern vs 
other dermoscopic profiles (81.8% vs 32.9%; P  =  .003). In line with these findings, a reticular 
vascular pattern also was more frequently associated with daily need for AMT (compared with all 
other cases) when adults (78.6% vs 44.2%; P  =  .02) and children (75.0% vs 26.3%; P  =  .07) were 
separately considered. 
Table 4. Need for Antimediator Therapy Among Patients With Mastocytosis in the Skin With 
Different Dermoscopic Patterns  
  
 
 
 
 
In univariate analysis, the following variables were included: clinical form (ie, MPCM, PM, NM, 
TMEP, and mastocytoma), dermoscopic pattern (ie, light-brown blot, pigment network, reticular 
vascular, and yellow-orange blot), sBt level, and age group (ie, adults and children). Multivariate 
analysis of predictive disease features for the need for daily AMT (Table 5) showed that the 
combination of sBt level (ie, >10 ng/mL), PM, and a reticular vascular pattern was the most 
informative independent factor; of note, no patients displayed all 3 factors simultaneously. On the 
basis of these results, a scoring system was built that proved to have high efficiency (positive 
predictive value, 0.9; 95% confidence interval [CI], 0.78-1.03; negative predictive value, 0.69; 0.60-
0.78) to properly classify patients with MIS according to the need for AMT when at least 2 of those 
factors are simultaneously present ( ≥2 of 3). These results contrast with predictive values observed 
when 1 or more of those factors are present (score of ≥1 of 3) (positive predictive value, 0.65; 95% 
CI, 0.53-0.76; negative predictive value, 0.86; 0.78-0.95). 
Table 5. Univariate and Multivariate Analyses of Predictive Factors for the Need for Daily 
Antimediator Therapy  
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To our knowledge, only 1 study in a small series of patients with mastocytosis (ie, 3 patients with 
TMEP and 3 with UP) has been published so far,18 in which 2 different dermoscopic patterns were 
described (ie, a pigment network and a vascular pattern). Of interest, the 2 patterns reported in this 
study showed histologic correlation with UP and TMEP, respectively. Several years before, Arpaia et 
al19 had described the dermoscopic pattern of a solitary maculopapular mastocytosis lesion as a 
delicate pale pigmented network. We report on the largest series of dermoscopic patterns observed 
in mastocytosis described so far in the literature. Overall, 4 clearly distinguishable dermoscopic 
patterns were identified: light-brown blot, pigment network, reticular vascular, and yellow-orange 
blot. 
The light-brown blot pattern was the most frequent dermoscopic pattern in our series. It accounted 
for a large proportion of all patients with MPCM and PM. Dermoscopic findings in these patients 
were similar to those observed in acral nevus20 and some actinic lentigos (S.V.-G. et al, unpublished 
data, January 2009). 
In turn, dermoscopic features of patients with a pigment network pattern were consistent with 
previously reported data pertaining to mastocytosis, and they have been related to the potential 
accumulation of melanin in the basal layer of the epidermis due to proliferation of MC within the 
dermis.21 This pattern typically is seen in melanocytic lesions, but it also can be detected in 
nonmelanocytic lesions other than mastocytosis, such as dermatofibroma,22 solar lentigo,23 
pigmented seborrheic keratoses,24 accessory nipple,25 Kaposi sarcoma,19 and even healthy skin.26 In 
our series, the pigment network pattern was present in approximately one-third of all patients with 
mastocytosis, with a slight predominance among those with MPCM and PM, similar to the light-
brown blot pattern profile. 
Thin telangiectasias detected in the reticular vascular pattern occur due to the presence of 
numerous proliferating vessels within the papillary dermis, which could reflect local release of MC-
derived angiogenic factors.27 The vascular dermoscopic pattern has been previously described in 
clear cell acanthoma,28 nonpigmented eccrine poromas,29 - 30 squamous cell carcinoma,31 amelanotic 
melanoma,32 and porocarcinoma.33 Of interest, this pattern of thin telangiectasia is not seen 
commonly in these other conditions. In our series, a reticular vascular pattern, in which MCs are 
typically located around dilated capillaries of the superficial plexus of the upper dermis, was 
systematically found in patients with TMEP and in a small proportion of those with MPCM. 
The yellow-orange blot dermoscopic pattern has been reported in a wide variety of skin lesions 
characterized by a xanthogranulomatous dermal infiltrate, which include juvenile 
xanthogranuloma,34 sebaceous hyperplasia,35 - 36 reticulohistiocytoma, xanthomatous 
dermatofibroma, and adult xanthogranuloma.37 Of interest, in our series, a similar yellow-orange 
blot pattern was systematically observed among children with mastocytoma and in approximately 
half of all patients with NM. 
Also, a clear association between the subtype of MIS and these dermoscopic patterns is 
demonstrated. On the basis of these observations, a question remained regarding the potential 
effect of such patterns on the behavior of the disease and the severity of MC mediator release –
associated symptoms. In this regard, our results clearly show that high sBt levels (ie, >10 ng/mL), 
together with a PM and the presence of a reticular vascular dermoscopic pattern, are highly 
predictive of the daily need for AMT. Currently, it is well known that sBt levels correlate with the 
overall MC burden38 - 39 ; in fact, an sBt level higher than 20 ng/mL is highly suggestive of systemic 
involvement in MIS, and it is 1 of the 4 World Health Organization minor criteria for diagnosis of 
systemic mastocytosis.7 Furthermore, increased sBt levels also have been associated with the 
severity of MC mediator release symptoms not only in mastocytosis but also in allergic diseases.40 - 42 
In our study, sBt levels were higher in adults compared with children, in accordance with a higher 
frequency of systemic involvement and a longer follow-up since the onset of the disease in adults. 
Nevertheless, higher sBt levels were associated with a more frequent need for daily AMT in the adult 
and pediatric groups. In line with these findings, multivariate analysis showed that sBt levels but 
not patient age proved to be a powerful independent predictive factor of the need for daily AMT, 
supporting the notion that tryptase levels by themselves are a powerful predictive factor of a more 
symptomatic disease. 
In line with previous observations,18 all patients with TMEP in our series showed a reticular vascular 
dermoscopic pattern. However, this pattern also was detected in some patients with MPCM; of 
interest, these latter patients more frequently required daily AMT than other patients with MPCM. 
Overall, the presence of a reticular vascular pattern was associated with an increased need for daily 
AMT; on the basis of these findings, it could be hypothesized that in combination with other 
variables, dermoscopy could provide additional help in the identification of patients at risk for more 
severe symptoms, independently of tryptase levels or the clinical subtype of MIS, as confirmed in 
our study by multivariate analysis. Another disease features that proved to be associated with more 
severe symptoms was the clinical form of MIS; PM was associated with a higher proportion of 
patients receiving daily AMT, but solitary mastocytoma was less symptomatic, with no patients 
needing daily AMT. At least in adults, this could occur due to a higher MC burden, as supported by 
the extremely higher sBt levels observed within this group of patients. 
A limitation of our study is that patients previously diagnosed as having mastocytosis were 
evaluated. A future prospective study including dermoscopy evaluation at the time of disease 
diagnosis may clarify whether dermoscopy may predict better evaluation in the future. 
The results of this study reveal that 4 dermoscopic patterns were evident in MIS, which can be easily 
evaluated in the diagnostic workup of cutaneous mastocytosis. However, these patterns are not 
totally specific for MIS, so the diagnosis needs to be confirmed by the results of a skin biopsy in 
most cases. The dermoscopic patterns, in combination with sBt levels and the clinical forms of MIS, 
also provide useful information for the identification of more symptomatic forms of the disease that 
will require daily AMT. Strict and prospective follow-up of patients can allow the possibility of 
detecting changes in dermoscopic patterns throughout the evolution of the disease (ie, children with 
a progressive decrease in skin lesions) or for the follow-up of response of skin lesions to different 
therapies, such as psoralen –UV-A, cytoreductive, or targeted therapies. 
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